Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-154 in Moderately to Severely Active Crohn's Disease
NCT05068284Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in Crohn's disease (10 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants Achieving Endoscopic Response Per Simple Endoscopic Score for Crohn's Disease (SES-CD) at 12 weeks. Started Jan 2022; status: terminated.
02
Drugs
ABBV-154
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05068284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068284.